- Home
- SNY vs GSBC Comparison
SNY vs GSBC Comparison
Compare SNY & GSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- GSBC
- Stock Information
- Founded
- SNY 1994
- GSBC 1923
- Country
- SNY France
- GSBC United States
- Employees
- SNY N/A
- GSBC N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- GSBC Major Banks
- Sector
- SNY Health Care
- GSBC Finance
- Exchange
- SNY Nasdaq
- GSBC Nasdaq
- Market Cap
- SNY 123.6B
- GSBC N/A
- IPO Year
- SNY N/A
- GSBC N/A
- Fundamental
- Price
- SNY $53.63
- GSBC $54.79
- Analyst Decision
- SNY Buy
- GSBC Hold
- Analyst Count
- SNY 2
- GSBC 2
- Target Price
- SNY $62.50
- GSBC $59.50
- AVG Volume (30 Days)
- SNY 3.6M
- GSBC 38.4K
- Earning Date
- SNY 04-24-2025
- GSBC 04-16-2025
- Dividend Yield
- SNY 3.08%
- GSBC 2.89%
- EPS Growth
- SNY 39.56
- GSBC 10.51
- EPS
- SNY 5.45
- GSBC 5.60
- Revenue
- SNY $48,817,552,946.00
- GSBC $219,572,000.00
- Revenue This Year
- SNY $5.35
- GSBC N/A
- Revenue Next Year
- SNY $6.69
- GSBC $2.27
- P/E Ratio
- SNY $18.87
- GSBC $9.78
- Revenue Growth
- SNY N/A
- GSBC N/A
- 52 Week Low
- SNY $45.80
- GSBC $47.57
- 52 Week High
- SNY $60.12
- GSBC $68.02
- Technical
- Relative Strength Index (RSI)
- SNY 50.20
- GSBC 51.83
- Support Level
- SNY $50.46
- GSBC $50.95
- Resistance Level
- SNY $51.64
- GSBC $57.68
- Average True Range (ATR)
- SNY 1.60
- GSBC 2.30
- MACD
- SNY 0.15
- GSBC 0.57
- Stochastic Oscillator
- SNY 65.92
- GSBC 65.47
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.